Articles On Alchemia (ASX:ACL)

Optiscan sponsoring clinical study for head and neck cancer surgery in Perth using its InVue and InForm technology The study is being led by prominent head and neck cancer surgeon Dr Chady Sader Data generated will support US FDA regulato...

Optiscan strives for ‘live biopsies’ for head and neck cancers LTR Pharma wins ethics clearance for fresh erectile dysfunction trial Noxopharm’s quest to cure lupus inches a step further Optiscan (ASX:OIL) will launch an imaging study of...

Highlights New study explores advanced real-time  Collaboration aims to expand digital pathology usage Technology seeks to deliver stronger surgical insights The short selling sector continues to shift as innovative medical techno...

Analysts at Macquarie believe there are several significant tailwinds for ASX All Ords healthcare stock Integral Diagnostics Ltd (ASX: IDX) in the coming year, and have a bullish price target on the company's shares. Integral Diagnostics...

The ASX small-cap stock Australian Clinical Labs Ltd (ASX: ACL) has fallen more than 20% in 2025 to date, as the chart below shows. I'm calling this ASX healthcare share cheap because of a few different reasons. Australian Clinical La...

Optiscan signs collaboration deal with Australian Clinical Labs to support rollout and testing of its InForm digital pathology platform Deal enables InForm to be validated in real-world conditions with imaging data collected from broad ran...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

There has been a lot of mergers and acquisitions (M&A) activity in recent months. This hasn't gone unnoticed by the team at Macquarie Group Ltd (ASX: MQG). So much so, the broker has run its takeover screen to see if there are any takeo...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. At the time of writing, the benchmark index is down 0.1% to 9,018.4 points. Four ASX shares that are not letting that hold them back today are...

Australian Clinical Labs Ltd (ASX: ACL) has announced a buyback of up to 10% of its issued capital, sending its share price more than 5% higher on Thursday. But the company's share price remains currently well down on where it was this t...

Highlights Key Australian companies witnessed notable market attention this week. Resource, retail, and healthcare sectors emerged in focus across the ASX stock market. Broader ASX 200 sentiment reflects shifting investor in...

Australian Clinical Labs (ASX: ACL) has agreed to pay a $5.8 million penalty over a cyberattack in 2021 that led to the theft of personal data of staff and patients at Medlab, a pathology business that the company had acquired in a deal wor...

Strong growth in healthcare service provision in August signals good news for healthcare stocks, with Macquarie analysts tipping Integral Diagnostics Ltd (ASX: IDX) shares to pile on more than 20% in gains. Medicare statistics for Augu...

Highlights Global indices extend upward trajectory Gold surges to new record levels Key ASX company movements in focus ASX 200 outlook strengthens as Wall Street hits records and gold surges, with key ASX-listed companies like Cat...

Highlights Three established ASX companies trading close to yearly lows Insights into healthcare and construction industries shaping long-term demand Broader trends across ASX sectors and index categories The ASX stock market rema...

When reading ASX share market news and analysis, we can spend a lot of time on the stocks we already own and the ones we wish we had bought before a big rise, etc.  We've all sat there and thought, "If only I'd just invested X amount int...

Highlights Historical data shows September is the weakest month for the Asx 200, with negative average returns across decades. Market corrections have historically clustered in September, coinciding with global volatility and bon...

Highlights Pilbara Minerals, Rio Tinto, and Fortescue continue prolonged technical breakdowns ANZ Group enters the Downtrends Scan List despite recent strength in banking Droneshield, Xero, and Zip Co. among the strongest tr...

Doctor visits dipped in April, reversing a recovery trend Mayne Pharma threatens to go legal in takeover dispute … but peace erupts at Cann Group with settlement of legal spat   We’re either a healthy lot, rely on Dr Google or simply can’...

With Labor having secured a resounding Federal election win and a majority government, you may be wondering which S&P/ASX 200 Index (ASX: XJO) stocks are best placed to gain from upcoming policy rollouts. If so, you're not alone! The go...

The US health sector shows signs of stabilising as chaos subsides Immutep will meet with the FDA following “excellent” follow-on trial results When it comes to its sagging share price, Immuron leaves blame-shifting to the defeated Liberals...

It’s up and go time for LTR in the US market All the budget healthcare news – and it’s a short item Prescient launches phase 2a study for a rare blood cancer   The developer of a nasal spray-mist erectile dysfunction (ED) treatment, LTR P...

  Australian Clinical Labs says GP and pathology visits are running below the long-term average Investors applaud EZZ’s half-year numbers Budget medical pot stymies Vitura’s results   As the dwindling number of GP bulk billers becomes a...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

ASX healthcare shares finished in the red on Friday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) falling 1.11% while the S&P/ASX 200 Index (ASX: XJO) also tumbled 0.5%. In a recent note, fund manager IML identified th...

S&P/ASX All Ordinaries (ASX: XAO) shares are up 0.58% to 8,606.1 points at the time of writing on Thursday. Meantime, Tamim Asset Management has issued a note on three ASX All Ords shares to buy. The broker says these stocks offe...

  US stocks climbed overnight, with the S&P 500 reaching a new record following the release of encouraging U.S. economic data. The broad market index rose 0.40 per cent to 5,745.37, achieving both an all-time high during the session and...

S&P/ASX All Ordinaries Index (ASX: XAO) share Australian Clinical Labs Ltd (ASX: ACL) is trading 2.1% higher at $3.40 per share. The All Ords Index is also up 0.84% to 8,264.3 points at the time of writing. It seems investors in t...

Fund manager Crescent Capital has announced its complete exit from Australian Clinical Labs (ASX: ACL), marking a significant shift in its investment strategy. Crescent Capital has divested its 30.12 percent stake in ACL through a block tra...

In a notable rebound, the Australian share market demonstrated resilience as it saw broad gains following a rally on Wall Street. The benchmark S&P/ASX 200 index advanced by 0.6 percent, or 44.30 points, to reach 8032.20. This brings it...

Highlights: ASX 200 futures indicate a positive opening with a rise of 50 points, driven by a strong overnight performance in US markets and an uptick in commodity prices. The US core CPI came in hotter-than-expected, yet markets reb...

  US stocks took a sharp downturn on Tuesday as technology shares faltered and new economic data reignited concerns about the health of the economy. The Dow Jones Industrial Average fell by 626.15 points, or 1.51 per cent, closing at 40,936...

US stocks took a sharp downturn on Tuesday as technology shares faltered and new economic data reignited concerns about the health of the economy. The Dow Jones Industrial Average fell by 626.15 points, or 1.51 per cent, closing at 40,936.9...

The ASX200 closed down more than 2% at 7,943 points. Despite hitting a fresh all-time record yesterday, the bourse retreated down below the 8,000 level. The ASX200 dipped along with Asian markets as stocks were hammered. The magnitude...

Monitoring short interest can provide valuable insights into market sentiment and potential concerns about company performance. This week’s ASIC short position report highlights the ASX shares currently attracting the most attention from sh...

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

Highlights:  ASX 200 futures fall 1.09%, mirroring losses in major US indices and mixed global economic updates.  Big Tech stocks showed mixed results overnight, with Meta and Nvidia gaining, while Apple, Alphabet, and Amazon decline...

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

Some experts have revealed where they see value within the S&P/ASX 300 Index (ASX: XKO) share landscape. Share prices are always changing, so when valuations adjust, it can open up opportunities if something moves from being fair va...

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

The Australian share market may be trading near its record high but that hasn't stopped some ASX 300 shares from hitting new 52-week lows. Three such shares that have made these unwelcome milestones are listed below. Is this recent weakness...

The biomedical treatment of disease and injury is what we call Pathology. Needles. Blood. Tissue. Other gross things. Etc. From the commonplace lab services which take and test our blood – to the cutting edge biological research of medical...

The biomedical treatment of disease and injury is what we call Pathology. Needles. Blood. Tissue. Other gross things. Etc. From the common place lab services which take and test our blood – to the cutting edge biological research of medical...

  US stocks slid as mixed economic data raised fears that stagflation may rear its ugly head, as growth numbers came in weaker than expected and price growth higher than expected. The Dow Jones fell 0.98 per cent. The S&P 500 closed dow...